Continuing Medical Education
The American Society of Pediatric Hematology/Oncology’s 30th Annual Meeting will offer CME credit for those sessions attended and evaluated. A certificate will be issued upon receipt of submission of the evaluation.
The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 24.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ASPHO offers its meeting evaluation in an online format. The online evaluation may be completed during the meeting or after attendees have returned home. Participants will receive their certificate immediately when they submit their evaluations online. We encourage all attendees to complete this evaluation regardless of whether they are seeking CME credits.
Intended Audience and Purpose
The Annual Meeting of the American Society of Pediatric Hematology/Oncology is designed to provide residents, fellows, investigators, and practitioners involved in the dynamic and rapidly evolving discipline of pediatric hematology/oncology with state-of-the-art education in the subspecialty.
Comprehend new information in pediatric hematology/oncology, including the latest in basic and clinical research.
Apply knowledge gained in all areas of pediatric hematology/oncology investigation and practice.
Assemble a network of professional colleagues with whom you can solve problems, share experiences, and provide mutual professional support.
Specifically, at the end of the meeting, we expect participants will be better able to:
Bone marrow transplant: Discuss the impact of MRI status of pre- and post-SCT in patients with T-cell ALL.
Cancer predisposition: Identify cancers and other features associated with predisposition syndromes and the genes involved in these syndromes.
Pediatric thrombosis: Discuss the challenges of design and implementation of clinical trials and recognize areas of active investigation in pediatric thrombosis.
Liver tumors: Define prognostic factors and the current risk stratification system for pediatric patients with liver tumors and describe treatment recommendations, including surgical guidelines.
Inherited hematologic diseases: Discuss the utility of next generation sequencing for FVIII and Factor IX genes. Describe the characteristics of patients with GATA2 mutations and summarize the role that PIK3CA plays in vascular anomalies and other overgrowth syndromes.
Palliative care: Enhance the understanding and improve utilization of the concept of concurrent care. Discuss stress strategies for identifying and referring patients to hospice and palliative care services.
Tumor microenvironment: Identify mechanisms of T-cell activation and inhibition and discuss new therapeutic approaches of checkpoint blockade in pediatric cancers. Increase understanding of the mechanism of TGFB-1 inhibition by the innate immune response in neuroblastoma and new methods of circumvention.
Diversity: Increase awareness of how cultural and racial differences affect health outcomes. Improve understanding of how our biases affect patient trust and outcomes and develop tools for improvement.
Platelets: Discuss recent findings relevant to inherited platelet disorders, including history, clinicopathologic features, suggested diagnostic and therapeutic approaches, and molecular basis.
AYA sickle cell: Provide management techniques for priapism, avascular necrosis, and chronic pain in patients with SCD.
Langerhans cell histiocytosis (LCH): Describe the mutations and pathophysiology of LCH and learn about the targeted therapies available.
Opportunistic infections: Delineate risk factors with both viral and fungal opportunistic infections in the immunocompromised patient and identify the safety and efficacy of antifungal and antiviral agents.
Pediatric Blood & Cancer: Discuss the review process for a submitted manuscript and identify what reviewers and editors consider as they review manuscripts.
ASPHO requires that planners and presenters disclose the existence of any relevant financial or other relationship they and/or their spouse/partner have with the manufacturers of any commercial interest (defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients) whose products or services relate to the topics presented. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product. The Certification and Continuing Education Committee reviews potential conflicts of interest as submitted by planners and presenters and resolves such conflicts so as to ensure the content of the activity is aligned with the interests of the public.
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO or PBMTC.
Convenient Maintenance of Certification (MOC) Opportunities
ASPHO will offer two opportunities to obtain American Board of Pediatrics (ABP) Maintenance of Certification (MOC) Part 2 points:
1. Maintenance of Certification Learning Session on Saturday, April 29, at 11:45 am. At the conclusion of this popular session, participants can submit their answers to the ABP MOC for scoring to receive up to 10 MOC Part 2 points. The fee to attend is $50, and advanced registration is required.
2. ASPHO will offer case-based, multiple-choice questions written by members of the Program Committee based on specific sessions at the annual meeting. When purchased, attendees will be able to access the questions online as part of the evaluation. After an overall score of 70% or more is achieved, each participant will receive 10 ABP MOC Part 2 points. Participants can have unlimited access to the multiple-choice questions for 1 year. The fee is $50, and advanced registration is required.